Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
Nexalin Technology (NXL) has regained compliance with Nasdaq's minimum bid price requirement, with its stock price above $1.00 for 21 consecutive days. The company must now meet a $2.5M stockholders' equity requirement by January 4, 2027, to maintain listing. Nexalin also announced a distribution agreement for South American markets and progress in U.S. clinical trials, according to the company.
How this was made
The 30-second read
Why it matters
Nasdaq’s written confirmation removes immediate bid-price delisting risk, but the Hearings Panel exception still requires meeting the $2.5m stockholders’ equity requirement by Jan 4, 2027, with potential reconsideration.
Market read
This is a listing-compliance milestone that can affect near-term trading risk premia, while the remaining equity deadline keeps uncertainty elevated.
What to watch
Traders may focus on the company’s ability to raise capital to meet the stockholders’ equity requirement, not just the bid-price metric that has already been satisfied.
Background
Nexalin previously underwent a reverse stock split and then needed to re-establish Nasdaq’s minimum bid price compliance under Listing Rule 5550(a)(2).
Ticker impact
Nasdaq confirmed NXL regained the $1.00 minimum bid price for 21 straight days after its reverse split, avoiding immediate delisting risk.
Likely modest relief bid as traders price reduced immediate delisting risk, offset by ongoing equity-compliance uncertainty.
The article is a direct Nasdaq compliance update tied to listing rules, but it also highlights a remaining equity condition with no outcome yet.
Market effects
Highlights ongoing Nasdaq listing compliance risk management for small-cap biotech/medtech issuers, especially post reverse split.
None material beyond US listing mechanics.
Limited, as the catalyst is Nasdaq continued-listing compliance rather than global demand or regulation.
Counterpoint
The bid-price fix may be viewed as temporary window dressing if equity compliance requires financing that could be dilutive.
Key entities
- companyNexalin Technology, Inc.
Nasdaq-listed neurostimulation company receiving confirmation of regained minimum bid price compliance.
- regulator/venueNasdaq Stock Market LLC
Exchange authority confirming compliance with Listing Rule 5550(a)(2).
- regulator/venueNasdaq Hearings Panel
Granted continued listing request and set the equity compliance deadline.
